Senior Editor, Diagnostic Imaging
Can AI-Powered Virtual Biopsies Improve Detection of Breast Lesion Subtypes on Digital Mammography?
October 27th 2022In separate test sets of Israeli women and United States women who had either ductal carcinoma in situ or invasive breast cancer, emerging artificial intelligence (AI) algorithms achieved an area under the curve (AOC) of 88 percent and 80 percent, respectively, for malignancy detection.
Transvaginal Ultrasound or MRI: Which is More Effective in Evaluating Endometrial Cancer?
October 26th 2022In a new study looking at pre-operative assessment of low-grade endometrial cancer, researchers found that while magnetic resonance imaging (MRI) had 20 percent higher specificity than transvaginal ultrasound for deep myometrial invasion, there was no difference in sensitivity.
Could an Emerging PSMA/PET Imaging Agent Improve the Detection of Recurrent Prostate Cancer?
October 25th 2022In a recent video interview from the American Society for Radiation Oncology (ASTRO) Annual Meeting, Benjamin Lowentritt, MD discussed the challenges of conventional imaging in diagnosing prostate cancer recurrence and the potential of an emerging high affinity, radiohybrid prostate-specific membrane antigen/positron emission tomography (PSMA/PET) imaging agent.
Study Suggests Shorter Duration of Radiation Therapy is Effective for High-Risk Prostate Cancer
October 24th 2022Five weeks of radiation therapy is just as effective as eight weeks of radiation treatment for men with high-risk prostate cancer, according to new research presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting.
Philips Gets FDA Nod for MRI Head and Neck Radiotherapy Application
October 20th 2022For physicians performing radiotherapy treatment of soft tissue tumors in the head and neck, the MRCAT Head and Neck offers an artificial intelligence (AI) application that allows the use of magnetic resonance imaging (MRI) as the primary or sole imaging for procedure planning.
HeartFlow Garners FDA Clearances for Two AI-Powered Assessment Tools with CCTA
October 20th 2022Plaque Analysis and RoadMap Analysis, two artificial intelligence (AI)-enabled assessment products, may enhance clinical evaluation of coronary artery disease (CAD) on cardiac computed tomography angiography (CCTA).
GE Healthcare Launches Omni Legend PET/CT System at EANM Congress
October 17th 2022The inclusion of digital bismuth germanate (BGO) detector material with the Omni Legend system reportedly more than doubles the sensitivity of older PET/CT devices, improves scan times, and enhances the detection of small lesions.
Can Increased Post-Op Surveillance Chest CT Have an Impact for Colorectal Cancer Patients?
October 17th 2022Out of 1,600 patients who had surgery for colorectal cancer, nearly 15 percent had pulmonary metastases within 15.4 months and higher-risk patients experienced lung metastases within three months, according to new research presented at the Scientific Forum of the American College of Surgeons Clinical Congress.
Emerging Advances with PET/CT Imaging in Pediatric Radiology
October 14th 2022In a recent video interview, Andrew Trout, MD discussed key attributes and efficiencies in utilizing the Discovery MI Gen 2 digital positron emission tomography/computed tomography (PET/CT) system at the Cincinnati Children’s Hospital Medical Center.
GE Healthcare Announces Moves to Bolster Supply of Iodinated Contrast Media for CT and X-Ray Imaging
October 14th 2022A multi-year agreement with a large Chile-based supplier of raw iodine is part of GE Healthcare’s commitment to increase the production of iodinated contrast media, commonly used in computed tomography imaging, by 30 million annually in 2025.
Could a New PSMA-Derived Radiomics Model Help Detect Intraprostatic Lesions on PET/CT?
October 13th 2022An emerging radiomics model, derived from 68Ga-PSMA-11 PET, reportedly offers a superior area under the curve (AUC) and higher sensitivity than radiologist assessment in detecting intraprostatic lesions via positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer.
Could Brain MRI Screening be Beneficial for Patients with Inflammatory Breast Cancer?
October 11th 2022While current consensus guidelines do not recommend the use of brain MRI screening in patients with breast cancer, a new study shows significantly elevated risks for the development of central nervous system metastasis in patients with inflammatory breast cancer.
Adjunctive AI Software for Brain MRI Gets FDA Clearance for Assessing High-Grade Gliomas
October 10th 2022Incorporating artificial intelligence (AI)-based technology, Neosoma HGG reportedly demonstrated a 95.5 percent accuracy rate in measuring brain tumor volume on brain magnetic resonance imaging (MRI) scans at various points during the treatment of patients with high-grade gliomas.
Digital Breast Tomosynthesis and Breast Density: What a New Study Reveals
October 6th 2022In a large study of nearly 100,000 women, researchers found that the combination of digital breast tomosynthesis (DBT) and synthesized mammography had more than triple the detection rate for invasive breast cancer in extremely dense breasts in comparison to digital mammography alone.
Study Looks at Potential Impact of Expanded Eligibility for Low-Dose CT Lung Cancer Screening
October 6th 2022Modifications to pack-year history and smoking quit duration thresholds beyond those recommended in the 2021 United States Preventative Services Task Force (USPSTF) criteria for low-dose computed tomography lung cancer screening may more than double the number of increased lung cancer cases physicians would see with application of the 2021 USPSTF screening criteria.
Study Finds No Benefit to MRI Screening in Women with High-Risk Breast Lesions
October 3rd 2022In a study involving nearly 700 patients with atypical ductal or lobular hyperplasia, or lobular carcinoma in situ, researchers found no difference in four-year breast cancer detection rates between women who had screening mammography and breast magnetic resonance imaging (MRI), and women who only had mammography screening.
Prospective MRI Study Reveals Impact of Opioid Exposure on the Fetal Brain
September 30th 2022Researchers found that in utero opioid exposure resulted in seven out of 14 2D biometric measurements of the fetal brain being smaller on magnetic resonance imaging (MRI) scans in comparison to fetuses without opioid exposure.
MRI Deep Learning Software from GE Healthcare Gets Expanded FDA Clearance
September 29th 2022AIR Recon DL, a deep learning-based image reconstruction software, will now be available with 3D sequences as well as PROPELLER motion-insensitive sequences on magnetic resonance imaging (MRI) scanners from GE Healthcare.
A Closer Look at Ultrasound and MRI Alternatives for Head and Neck Imaging
September 29th 2022In light of recent shortages of iodinated contrast media, researchers from Australia suggest in a new publication that ultrasound and magnetic resonance imaging (MRI) can be viable first-line imaging options for a number of non-urgent presentations of the head and neck.
What a New Meta-Analysis Reveals About Breast Density, Mammography and MRI Screening
September 28th 2022Assessing data from 386,590 women, researchers noted that women with extremely dense breast tissue have more than double the risk for breast cancer in comparison to women with average breast density and nearly four times the risk of women with extremely fatty breast tissue.
FDA to Review Blue Earth Diagnostics' Emerging PSMA/PET Agent for Prostate Cancer
September 27th 2022One prospective multicenter study found the radiohybrid prostate-specific membrane antigen (PSMA) agent 18F-rhPSMA-7.3 had an 83 percent detection rate in nearly 400 men with suspected prostate cancer.
Five Takeaways from New Consensus Recommendations for CT Imaging and Reporting in Patients with CAD
September 23rd 2022In an update of the original CAD-RADS™ consensus document on coronary artery disease (CAD) imaging and reporting published in 2016, expert panelists incorporated emerging evidence for CAD-RADS 2.0 to recommend new categorization for coronary plaque burden and suggested modifiers to reflect the level of ischemia and high-risk plaque in patients undergoing cardiac computed tomography.
Ultrasound-Based Breast Imaging Device Gets FDA Clearance for Fibroglandular Volume Metrics
September 23rd 2022The ability of QT Imaging’s QTscan, a quantitative transmission ultrasound modality, to calculate the ratio of fibroglandular volume to total breast volume may facilitate assessment of ongoing breast cancer treatments or selective hormone receptor modulation therapies.